Observational studyAdvances in therapy2020
SABINA: An Overview of Short-Acting β
Observational study in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 2 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Adverse Outcomes Associated With Short-Acting Beta-Agonist Overuse in Asthma: A Systematic Review and Meta-Analysis.Allergy · 2025Pooled it
- Perceptions, attitudes, and behaviors of asthma patients towards the use of short-acting β2-agonists: A systematic review.PloS one · 2023Pooled it
- SABA Overuse in Russia - Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study.Journal of asthma and allergy · 2022Trial
- Reducing short-acting beta-agonist overprescribing in general practice: Evaluation of a quality improvement programme in East London.The European journal of general practice · 2026Article
- Global under- and overprescribing of drugs-a scoping review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Airway inflammation and asthma control in patients using salbutamol or budesonide/formoterol reliever: a randomised, controlled study.ERJ open research · 2026Article
- Barriers and facilitators to practitioner prescribing and patient adoption of anti-inflammatory maintenance and reliever therapy (MART) for adult asthma: a qualitative study.BMC primary care · 2026Article
- Decarbonising Respiratory Care: The Impact of a Low-Carbon Salbutamol Pressurised Metered-Dose Inhalers.Allergy · 2026Article
- Article
- Climate Change and the Switch from Pressurised Metered-Dose Inhalers to Dry Powder Inhalers: A Proportionate Balancing of Risk and Reward?Pulmonary therapy · 2026Review
- Factors associated with asthma attack recurrence in Ecuadorian children: longitudinal study of potential impact of the COVID-19 pandemic lockdown.BMJ open respiratory research · 2025Article
- Over-reliance on short-acting beta-agonists (SABAs) in asthma: a mixed method study, in primary care, in Greece.NPJ primary care respiratory medicine · 2025Article
- Characteristics and management of patients attending primary asthma clinics in primary health care in the Kingdom of Bahrain: A cross-sectional study.Journal of family medicine and primary care · 2025Article
- Influence of Saharan Dust Intrusions on Respiratory Medication Dispensing.Medical sciences (Basel, Switzerland) · 2025Article
- Trends in inhaler use and associated carbon footprint: a sales data-based study in Europe.BMJ open respiratory research · 2025Article
- Article
- Burden of asthma by severity and exacerbation frequency among adult patients naive to biologic asthma therapy: A Finnish cohort study.The journal of allergy and clinical immunology. Global · 2025Article
- Optimizing adherence to medication to improve outcomes in asthma.Current opinion in pulmonary medicine · 2025Review
- Exploring the carbon footprint of severe asthma and change after biologic therapy initiation: an analysis of Northern Irish data.ERJ open research · 2025Article
- How to move towards more sustainable asthma care in Europe: an expert opinion paper.Breathe (Sheffield, England) · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlobally, individuals with asthma tend to overrely on short-acting β
methodsPrescription and/or dispensing data during 2006-2017 from electronic medical records and/or national patient registries in the United Kingdom (UK), Germany, Italy, Spain, and Sweden were analyzed. Individuals aged at least 12 years old with a current asthma diagnosis and no other chronic respiratory conditions were included. Asthma treatment step and severity were based on treatment guidelines in use in each individual country. The proportion of individuals prescribed SABA was measured during a 12-month period. SABA overuse was defined as at least three SABA canisters per year.
resultsMore than one million individuals with asthma were included across five European countries. Overall, the majority of individuals were over 45 years of age, except in Sweden (mean age 27.6 years) where individuals aged over 45 years were excluded to avoid a potential chronic obstructive pulmonary disease co-diagnosis. The study population was predominantly female (55-64%), except in the UK (46%). The prevalence of SABA overuse was 9% in Italy, 16% in Germany, 29% in Spain, 30% in Sweden, and 38% in the UK. In the UK, SABA overuse was greater in individuals with moderate-to-severe asthma versus individuals with mild asthma (58% versus 27%, respectively), while SABA overuse was similar in individuals with both mild (9-32%) and moderate-to-severe (8-31%) asthma in the other European countries.
conclusionsThe findings of this study from the SABINA program show that SABA overuse (at least three canisters per year) is common across Europe, despite the different healthcare and reimbursement policies of each country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.